Using sophisticated RNA sequencing technology, biomedical researchers can measure the activity of our genes across millions ...

“Hey model, if I prompt you with the marker genes for a cell type, can you complete the transcription factors that you believe would be highly expressed with expression of these genes?” posed ...

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...

Researchers at the University of Southampton have identified a new subtype of lymphoma which could pave the way to improved ...

Announcement of a podium presentation at a prestigious symposium, showcasing innovative research in cell therapy for type 1 diabetes. Presentation features promising clinical data on UP421, a novel ...

Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human ...

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...

Trying to document how single brain cells participate in networks that govern behavior is a daunting task. Brain probes called Neuropixels, which feature high-density silicon arrays, have enabled ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 ...

Researchers at the University of Southampton have identified a new subtype of lymphoma that could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer ...